Association between COVID-19 and cardiovascular disease
Autor
Srivastava, Kamna
Institución
Resumen
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which causes coronavirus
disease 2019 (COVID-19) has reached a pandemic level. SARS-CoV-2 infects host cells through
ACE2 receptors, leading to COVID-19-related pneumonia. The rapid increase in confirmed cases
makes the prevention and control of COVID-19 extremely serious. Real-time reverse
transcription-PCR (RT-PCR) assays remain the molecular test of choice for the etiologic diagnosis
of SARS-CoV-2 infection while radiographic findings (chest computed tomography [CT]) and
antibody-based techniques are being introduced as supplemental tools. Novel virus also cause
chronic damage to the cardiovascular system, and attention should be given to cardiovascular
protection during treatment for COVID-19.
Acute cardiac injury determined by elevated high-sensitivity troponin levels is commonly
observed in severe cases and is strongly associated with mortality. This review suggests that
cardiovascular comorbidities are common in patients with COVID-19 and such patients are at
higher risk of morbidity and mortality. The continuation of clinically indicated ACE inhibitor and
ARB medications is recommended in COVID-19. We review the basics of coronaviruses, novel
molecular targets for the coronaviruses with a focus on COVID-19, along with their effects on the
cardiovascular system.